CYP19A1 and ovarian dysfunction: Post-chemotherapy, undetectable AMH levels, together with diminished estradiol and heightened FSH, may indicate irreversible ovarian failure, thus permitting the safe administration of aromatase inhibitors without concurrent ovarian suppression [43].